ustekinumab psoriatic arthritis
Selected indexed studies
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (Ann Rheum Dis, 2024) [PMID:38503473]
- Ustekinumab in psoriatic arthritis and related phenotypes. (Ther Adv Chronic Dis, 2018) [PMID:30263103]
- A review of ustekinumab in the treatment of psoriatic arthritis. (Immunotherapy, 2018) [PMID:29439608]
_Worker-drafted node — pending editorial review._
Connections
ustekinumab psoriatic arthritis is a side effect of
Sources
- Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation. (2024) pubmed
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (2024) pubmed
- Ustekinumab in psoriatic arthritis and related phenotypes. (2018) pubmed
- A review of ustekinumab in the treatment of psoriatic arthritis. (2018) pubmed
- The safety of ustekinumab for the treatment of psoriatic arthritis. (2017) pubmed
- Ustekinumab-induced chronic lymphocytic leukemia in a patient with psoriatic arthritis. (2021) pubmed
- Psoriatic arthritis. (2016) pubmed
- Ustekinumab with or without methotrexate for psoriatic arthritis? (2023) pubmed
- Ustekinumab for the treatment of psoriatic arthritis: an update. (2014) pubmed
- Is ustekinumab effective for psoriatic arthritis with insufficient response to initial treatment? (2018) pubmed